DnB Asset Management
IOVA icon

DnB Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

DnB Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$118K Buy
+28,433
New +$108K ﹤0.01% 1260
2025
Q4 		– Sell
-124,045
Closed -$269K – 750
2025
Q3 		$269K Sell
124,045
-39,460
-24% -$93.2K ﹤0.01% 698
2025
Q2 		$281K Buy
163,505
+71,925
+79% +$179K ﹤0.01% 675
2025
Q1 		$305K Buy
91,580
+50,802
+125% +$262K ﹤0.01% 688
2024
Q4 		$302K Buy
40,778
+8,837
+28% +$81.9K ﹤0.01% 689
2024
Q3 		$300K Buy
31,941
+3,919
+14% +$37.1K ﹤0.01% 679
2024
Q2 		$224K Buy
28,022
+11,091
+66% +$119K ﹤0.01% 691
2024
Q1 		$251K Buy
+16,931
New +$197K ﹤0.01% 686

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

DnB Asset Management's IOVA Position: Q2 2026 in Review

DnB Asset Management opened a new position in Iovance Biotherapeutics (IOVA) in Q2 2026: 28,433 shares worth $118K. The stake represents ﹤0.01% of the portfolio and ranks #1260 among its holdings. This is a return to the name: DnB Asset Management previously reported a position in IOVA as recently as Q3 2025.

DnB Asset Management first reported a position in IOVA in Q1 2024 and has held it in 8 quarters since. The position peaked at $305K in Q1 2025. 211 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • DnB Asset Management held 28,433 shares of Iovance Biotherapeutics worth $118K as of Q2 2026.
  • Iovance Biotherapeutics was a new DnB Asset Management position in Q2 2026.
  • Iovance Biotherapeutics made up ﹤0.01% of DnB Asset Management's portfolio in Q2 2026, its #1260 holding.
  • DnB Asset Management first reported a position in Iovance Biotherapeutics in Q1 2024 and has held it in 8 quarters since.
  • DnB Asset Management's Iovance Biotherapeutics position peaked at $305K in Q1 2025.
  • 211 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.